Background: Type 2 diabetes mellitus is associated with increased cardiovascular risk. One laboratory marker for cardiovascular risk assessment is highsensitivity C-reactive protein (hsCRP). Methods: This cross-sectional study attempted to analyze the association of hsCRP levels with insulin resistance, b-cell dysfunction and macrovascular disease in 4270 non-insulin-treated patients with type 2 diabetes w2146 male, 2124 female; mean age "SD, 63.9"11.1 years; body mass index (BMI) 30.1"5.5 kg/m
Introduction
Patients with type 2 diabetes suffer from high cardiovascular morbidity and mortality based on extensive and accelerated arteriosclerosis (1) . Coronary arteriosclerosis is increasingly recognized as a major complication and the leading cause of death in subjects with diabetes (2) . It has been shown by laboratory and experimental studies that arteriosclerosis, as well as being a disease of lipid accumulation, represents a chronic inflammatory process (3) . Thus, inflammatory markers have been investigated to identify potential adjunctive predictors for global assessment of cardiovascular risk (4) (5) (6) . Several large-scale prospective epidemiological studies have demonstrated that highsensitivity C-reactive protein (hsCRP) is a strong independent predictor for risk of future myocardial infarction and other consequences of arteriosclerosis, even in patients without known macrovascular disease (7) (8) (9) (10) . With the recognition that inflammation is a critical component in the determination of plaque stability, CRP levels in the low-normal range were found to have predictive value for patients with acute coronary ischemia (11, 12) . Levels of hsCRP -1 mg/L, 1-3 mg/L and )3 mg/L have been suggested to define low-, moderate-, and high-risk groups, while levels )10 mg/L may indicate unspecific elevation consequent to a general inflammatory process (9) .
In this analysis of the IRIS-II study population (13-15), we investigated the prevalence of hsCRP in a large population of 4270 orally treated type 2 diabetes mellitus patients, and its correlation with the prevalence of insulin resistance, b-cell dysfunction and cardiovascular events.
Patients and methods
The epidemiological cross-sectional study was performed in German patients with orally treated type 2 diabetes mellitus (HbA 1c ) was measured by HPLC (Menarini, Neuss, Germany; reference range 4.4-6.0%). Glucose was determined using a glucose oxidase method (SuperGL; Ruhrtal Labortechnik, Delecke-Mö hnesee, Germany). Insulin and intact proinsulin were determined by means of specific immunoassays (Sciema, Mainz, Germany) as previously published (16) . HsCRP was assessed by means of a turbidimetric method (Olympus, Hamburg, Germany). Assessment of insulin resistance was performed by analysis of fasting intact proinsulin values or homeostatic model assessment (HOMA IR ) score calculation. Patients with intact proinsulin values exceeding the normal reference value of 11 pmol/L were considered to be insulin-resistant (14, 15) . In the case of normal intact proinsulin values, HOMA IR score calculation was applied, as previously published (17) . The estimate of insulin resistance by HOMA IR score was calculated using the following formula: fasting serum insulin (mU/mL)=fasting plasma glucose (mmol/L)/22.5. As described by Hedblad et al. in a non-diabetic population, patients with HOMA IR score values exceeding the 75th percentile (i.e., 2.0) were considered to have insulin resistance (18) . The b-cell dysfunction stage was assessed by considering steady state of insulin and intact proinsulin on the fasting morning, as previously reported (19) .
Statistical analysis
As hsCRP has been reported to be associated with body mass index (BMI), hsCRP concentrations were adjusted for BMI before further analysis (20) . To compare the means of the variables measured, Student's t-test, and the Mann-Whitney U-test were used. All tests were carried out as two-sided. Results with p-values less than 0.05 were considered statistically significant. All calculations were made with the SPSS statistical package (version 9.0; SPSS Inc., Chicago, IL, USA).
Results
The study was completed by 2146 male and 2124 female patients with type 2 diabetes on oral medication and/or diet wage (mean"SD) 63.9"11.1 years (range 21-96); disease duration 5.4"5.6 years (range 0-52); BMI 30.1"5.5 kg/m 2 (range 16.0-67.2); waist/ hip ratio 1.0"0.1 (range 0.6-1.4); HbA 1c 6.8"1.3% (range 4.2-16.0%)x. No significant differences in demographic data could be observed between male and female patients.
Stratification of the patients into the different b-cell dysfunction stages, as previously defined (19) , led to the following results: stage I (no insulin resistance or b-cell secretion disorder), 1042 patients (24.4%); stage II (insulin resistance without secretion disorder), 1658 patients (38.8%); and stage III (insulin resistance and secretion disorder), 1570 patients (36.7%). The clinical characteristics of these groups are given in Table 1 . Calculation of the mean hsCRP concentration in all three b-cell dysfunction groups revealed high risk levels for all stages of b-cell dysfunction. A higher cardiovascular risk was associated with more advanced stages of b-cell dysfunction (p-0.001), as shown in Figure 1 .
Stratification of the patients into the hsCRP risk groups as suggested by Ridker and Cook (9) revealed that 934 patients had low risk (hsCRP -1 mg/L, 21.8%), 1369 patients were in the medium-risk group (hsCRP 1-3 mg/L, 32.0%), and 1352 patients were in the high-risk group (hsCRP )3-10 mg/L, 31.6%). The number of patients with unspecific elevated hsCRP values ()10 mg/L) was 610 (14.3%).
The differences observed for both hsCRP-associated cardiovascular risk and severity of b-cell dysfunc- Figure 1 Stratification of patients (% distribution) with high and low cardiovascular risk (according to hsCRP risk group definition) into the b-cell dysfunction stages as defined by Pfü tzner et al. (19) . Higher cardiovascular risk is associated with a higher degree of b-cell dysfunction. Ridker and Cook (7, 9) , while the correlation with markers of glucose metabolism (HbA 1c , glucose) is less pronounced, although still significant because of the high number of patients. The association of hsCRP values with prescribed therapy is shown in Figure 2 . Patients receiving combination therapy of peroxisome proliferator activated receptor g (PPARg) agonists with metformin presented the lowest hsCRP mean values (p-0.05).
Discussion
The cross-sectional IRIS study was initially performed to identify diagnostic parameters for insulin resistance in non-insulin-treated patients with type 2 diabetes that are suitable for daily practice (13) (14) (15) . Analysis of the same patient population presented here was performed to evaluate the correlation between cardiovascular risk, as identified by hsCRP risk assessment and b-cell dysfunction, and insulin resistance. In our non-insulin-treated type 2 diabetes patients with approximately 5 years of disease duration, the prevalence of macrovascular complications was 20-30%. Serum levels of hsCRP were correlated with the severity of insulin resistance and b-cell dysfunction. All analysis groups, however, had hsCRP levels indicating high cardiovascular risk.
Chronic vascular inflammation may be the reason why hsCRP was elevated in our type 2 diabetes population. Strong correlations were evident between cardiovascular risk as assessed by hsCRP stratification and other parameters that are associated with increased risk or increased prevalence of cardiovascular complications in patients with type 2 diabetes, such as BMI, insulin resistance and elevated proinsulin (21) (22) (23) . No or only weak associations, however, were evident for age, disease duration and the metabolic markers HbA 1c and fasting glucose. This result is in line with previous reports demonstrating that postprandial glucose, rather than fasting glucose and HbA 1c , is a strong predictor for cardiovascular mortality in patients with type 2 diabetes, as it may increase adhesion molecule secretion by endothelial cells when glucose concentrations increase above toxic levels (24) .
A weakness of our study is the cross-sectional approach, which does not allow conclusions to be drawn about the impact of different therapeutic interventions on the metabolic and macrovascular risk scenario. It has, however, been demonstrated that impairment of b-cell dysfunction, as indicated by increased intact proinsulin levels, is associated with the use of insulinotropic substances, such as sulfonylurea drugs (15) . In this analysis the highest hsCRP levels were also observed in patients receiving sulfonylurea therapy. These results support the hypothesis that cardiovascular disease risk may be associated with sulfonylurea treatment, as suspected decades ago (25, 26) and reported again recently (27) . Unfortunately, contradicting reports from studies such as the UK Prospective Diabetes Study (UKPDS) did not involve well enough characterized patient populations to allow direct comparison of the results (28) . However, prospective studies using the same diagnostic markers as used in our current analysis have provided evidence of a beneficial impact of other therapeutic interventions compared to sulfonylurea therapy. Treatment of insulin resistance, e.g., using PPARg agonists seems to be an effective measure for decreasing cardiovascular and metabolic risk (29) (30) (31) (32) .
The importance of determining hsCRP in at-risk populations, such as diabetic patients, is further strengthened by recent reports suggesting that hsCRP is not only a risk indicator, but may also allow monitoring of arteriosclerosis regression during successful therapeutic interventions. Patients who have low CRP levels after statin therapy have better clinical outcomes than those with higher CRP levels, regardless of the resultant level of LDL cholesterol (33) . In the ''Reversal of Atherosclerosis with Aggressive Lipid Lowering'' study (REVERSAL), the reduced rate of progression of atherosclerosis associated with intensive statin treatment, as compared with moderate statin treatment, was significantly related to greater reductions in the levels of both atherogenic lipoproteins and CRP in patients with coronary artery disease (34) . The same may hold true for patients with type 2 diabetes. Whether determination of hsCRP can provide additional risk information in type 2 diabetes, similar to the analysis of Ridker et al. in the Framingham Risk Score population (35) , needs to be explored in prospective epidemiological trials.
The results of our analysis indicate that impaired insulin resistance and impaired b-cell function were associated with higher hsCRP levels and a higher prevalence of macrovascular complications. The clear association between hsCRP and other established or suspect risk markers support the suitability of hsCRP as a cardiovascular risk marker suitable for routine clinical use in type 2 diabetes mellitus.
